Peijia Medical Limited logo

Peijia Medical Limited

9996.HK

HKSEHealthcareMedical - Devices

Latest quote

HK$5.31

+HK$0.335 · +6.73%

Aug 24, 11:03 AM HKT

9996.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Peijia Medical Limited specializes in the innovation and development of advanced medical devices for transcatheter valve therapies and neurointerventional procedures. Their extensive portfolio of transcatheter valve solutions includes numerous TAVR (transcatheter aortic valve replacement) systems, such as TaurusOne, the retrievable TaurusElite, TaurusNXT (a non-glutaraldehyde dry-tissue system), TaurusApex (featuring polymer leaflets), and Trilogy. For mitral valve interventions, they offer the HighLife transseptal replacement system, SpyderOne (a transapical TMVR system), Sutra for coaptation augmentation, and the GeminiOne edge-to-edge repair system. They also provide the MonarQ and Peijia systems for transcatheter tricuspid valve replacement. Complementary devices supporting these procedures include the TaurusAtlas transfemoral balloon catheter, TaurusExplora pre-shaped guidewire, and introducer sheaths. In the neurointerventional field, Peijia Medical develops devices like the Jasper and Presgo detachable coils (including the Jasper SS variant), various intracranial adjunctive stents such as NeuroStellar, and the SacSpeed balloon dilatation catheter. Additional offerings comprise the Tethys AS aspiration catheter, Syphonet stent retriever, Neway balloon microcatheter, Fluxcap balloon guiding catheter, Presgo microcatheters and micro guidewires, Heralder guiding and distal access catheters, the Tethys intermediate catheter, and the Jasper power supply. Furthermore, the company engages in trading activities. Peijia Medical Limited was founded in 2012 and is headquartered in Suzhou, People's Republic of China.

Industry
Medical - Devices
Sector
Healthcare
Headquarters
CN
CEO
Yi Zhang
Listed since
May 15, 2020
Employees
1,022

Market position

Day range

Current HK$5.31

52-week range

Current HK$5.31

Open
HK$5.18
Previous close
HK$4.975
Volume
819K
0.8× average
Average volume
1.02M
Average daily volume
Market cap
3.56B HKD
Beta
0.59
Market reference 1
50-day average
HK$4.2978
+23.55% above average
200-day average
HK$5.5673
-4.62% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
3.44B CNY
P/E (TTM)
-15.17×
P/B (TTM)
1.64×
P/S (TTM)
4.27×
EV / EBITDA
-25.69×
Earnings yield
-5.66%
Free cash flow yield
-9.06%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
68.18%
Operating margin
-27.87%
Net margin
-28.52%
Return on equity
-11.02%
Return on assets
-7.65%
Return on invested capital
-8.37%

Financial health

Debt / equity
0.24×
Current ratio
1.21×
Altman Z-score
-0.26
Piotroski F-score
4 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends125%-80%-285%-490%Gross margin, FY2021: 70.06%Gross margin, FY2022: 70.25%Gross margin, FY2023: 73.76%Gross margin, FY2024: 70.45%Gross margin, FY2025: 68.18%Operating margin, FY2021: -438.57%Operating margin, FY2022: -176.43%Operating margin, FY2023: -97.65%Operating margin, FY2024: -38.89%Operating margin, FY2025: -27.87%Net margin, FY2021: -420.57%Net margin, FY2022: -162.58%Net margin, FY2023: -88.98%Net margin, FY2024: -36.81%Net margin, FY2025: -28.52%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 70.06%. Gross margin FY2022 70.25%. Gross margin FY2023 73.76%. Gross margin FY2024 70.45%. Gross margin FY2025 68.18%. Operating margin FY2021 -438.57%. Operating margin FY2022 -176.43%. Operating margin FY2023 -97.65%. Operating margin FY2024 -38.89%. Operating margin FY2025 -27.87%. Net margin FY2021 -420.57%. Net margin FY2022 -162.58%. Net margin FY2023 -88.98%. Net margin FY2024 -36.81%. Net margin FY2025 -28.52%.

Income trends

Revenue

712.87M CNY+15.82%

Operating income

−198.67M CNY+16.99%

Net income

−203.29M CNY+10.28%
Income trends across reported periods844.04M CNY319.37M CNY−205.3M CNY−729.97M CNYRevenue, FY2021: 136.53M CNYRevenue, FY2022: 250.83M CNYRevenue, FY2023: 441.13M CNYRevenue, FY2024: 615.48M CNYRevenue, FY2025: 712.87M CNYOperating income, FY2021: −598.8M CNYOperating income, FY2022: −442.55M CNYOperating income, FY2023: −430.76M CNYOperating income, FY2024: −239.35M CNYOperating income, FY2025: −198.67M CNYNet income, FY2021: −574.22M CNYNet income, FY2022: −407.81M CNYNet income, FY2023: −392.53M CNYNet income, FY2024: −226.58M CNYNet income, FY2025: −203.29M CNYFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 136.53M CNY. Revenue FY2022 250.83M CNY. Revenue FY2023 441.13M CNY. Revenue FY2024 615.48M CNY. Revenue FY2025 712.87M CNY. Operating income FY2021 −598.8M CNY. Operating income FY2022 −442.55M CNY. Operating income FY2023 −430.76M CNY. Operating income FY2024 −239.35M CNY. Operating income FY2025 −198.67M CNY. Net income FY2021 −574.22M CNY. Net income FY2022 −407.81M CNY. Net income FY2023 −392.53M CNY. Net income FY2024 −226.58M CNY. Net income FY2025 −203.29M CNY.
Metric (CNY)FY2025FY2024FY2023FY2022FY2021
Revenue712.87M CNY615.48M CNY441.13M CNY250.83M CNY136.53M CNY
Cost of goods sold226.82M CNY181.86M CNY115.76M CNY74.63M CNY40.88M CNY
Gross profit486.05M CNY433.62M CNY325.37M CNY176.2M CNY95.65M CNY
Research and development266.72M CNY233.13M CNY293.42M CNY373.13M CNY454.42M CNY
Selling, general, and administrative446.83M CNY479.44M CNY466.62M CNY365.06M CNY207.68M CNY
Operating expenses684.72M CNY672.97M CNY756.13M CNY618.75M CNY694.46M CNY
Interest income7.81M CNY22.48M CNY39.44M CNY46.63M CNY24.77M CNY
Interest expense11.73M CNY4.74M CNY178K CNY2.32M CNY186K CNY
Depreciation and amortization62.29M CNY53.41M CNY42.8M CNY36.01M CNY27.49M CNY
Operating income−198.67M CNY−239.35M CNY−430.76M CNY−442.55M CNY−598.8M CNY
Net income−203.29M CNY−226.58M CNY−392.53M CNY−407.81M CNY−574.22M CNY

Company facts updated Aug 24, 2026.

Earnings

Latest EPS result
-0.01

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates-0.01-0.2-0.39-0.58Q1 '23Q3 '23Q1 '24Q3 '24Q1 '25Q3 '25Q1 '26Q3 '26
Q1 2023, reported Mar 31, 2023: actual -0.535, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Aug 31, 2023: actual -0.335, estimate —, surprise —, Comparison unavailable. Q1 2024, reported Mar 28, 2024: actual -0.288, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 23, 2024: actual -0.107, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 25, 2025: actual -0.255, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 22, 2025: actual -0.11, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 25, 2026: actual -0.223, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 20, 2026: actual -0.012, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates742.56M537.64M332.73M127.82MQ1 '23MissQ3 '23MissQ1 '24MissQ3 '24MissQ1 '25MissQ3 '25MissQ1 '26No estimateQ3 '26Miss
Q1 2023, reported Mar 31, 2023: actual 150.38M HKD, estimate 487.74M HKD, surprise -69.17%, Miss. Q3 2023, reported Aug 31, 2023: actual 243.01M HKD, estimate 688.35M HKD, surprise -64.70%, Miss. Q1 2024, reported Mar 28, 2024: actual 239.35M HKD, estimate 698.69M HKD, surprise -65.74%, Miss. Q3 2024, reported Aug 23, 2024: actual 323.62M HKD, estimate 506.39M HKD, surprise -36.09%, Miss. Q1 2025, reported Mar 25, 2025: actual 334.33M HKD, estimate 386.63M HKD, surprise -13.53%, Miss. Q3 2025, reported Aug 22, 2025: actual 387.23M HKD, estimate 444.05M HKD, surprise -12.79%, Miss. Q1 2026, reported Mar 25, 2026: actual 399.93M HKD, estimate —, surprise —, Comparison unavailable. Q3 2026, reported Aug 20, 2026: actual 489.9M HKD, estimate 514.81M HKD, surprise -4.84%, Miss.

9996.HK peers

ETFs holding 9996.HK

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research 9996.HK

research.disclaimer